Certificates of analysis, by compound
Every figure on this page is computed from our corpus of independent, third-party lab certificates. No vendor marketing, no self-reported numbers. Choose a compound for its full aggregate purity and dose-accuracy profile, then read every underlying certificate. This index lists the 187 compounds with enough certificates to publish an aggregate profile — 61,463 of the 72,860 tested batches we hold. The rest sit in compounds too thinly tested to summarize, and are still reachable from their vendor pages.
187
Compounds indexed
61,463
Certificates here
72,860
In the full corpus
24
Testing labs
7
Categories
376
Zero-purity certs
Certificates from
Freedom DiagnosticsJanoshikFinnrick (Lab E)Finnrick (Lab G)Finnrick (Lab A)Peptide TestFinnrick (Lab C)Finnrick (Lab F)Finnrick (Lab D)Finnrick (Lab B)ChromateSR BIO LABS+12 more
GLP-1 & Incretins
6 compoundsRetatrutide
11,800 certificates
151 zero-purity
Median purity99.8%
Dose pass ±10%52%
Labs19
Vendors3601
View
Tirzepatide
8,415 certificates
77 zero-purity
Median purity99.8%
Dose pass ±10%56%
Labs20
Vendors2169
View
| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| Semaglutide 7 zero-purity2022-09 → 2026-07 · ↑ 54% over ↓ 9% under | 885 | 99.7% | 50% | 11 | 243 | |
| Cagrilintide2024-03 → 2026-08 · ↑ 56% over ↓ 6% under | 821 | 99.8% | 50% | 13 | 434 | |
| Survodutide2024-05 → 2026-08 · ↑ 51% over ↓ 10% under | 96 | 99.7% | 56% | 6 | 51 | |
| Mazdutide2024-04 → 2026-08 · ↑ 48% over ↓ 11% under | 90 | 99.5% | 65% | 7 | 48 |
Healing & Recovery
10 compoundsGHK-Cu
2,988 certificates
5 zero-purity
Median purity99.8%
Dose pass ±10%57%
Labs10
Vendors1473
View
BPC-157
2,801 certificates
34 zero-purity
Median purity99.4%
Dose pass ±10%38%
Labs14
Vendors1289
View
| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| BPC-157 + TB-5002025-03 → 2026-08 · ↑ 25% over ↓ 50% under | 1,486 | 99.3% | 25% | 2 | 967 | |
| TB-500 15 zero-purity2021-02 → 2026-08 · ↑ 61% over ↓ 7% under | 1,457 | 99.4% | 46% | 9 | 820 | |
| KPV2024-09 → 2026-08 · ↑ 63% over ↓ 7% under | 957 | 99.6% | 40% | 6 | 671 | |
| Thymosin Alpha-12022-08 → 2026-08 · ↑ 59% over ↓ 8% under | 545 | 99.7% | 47% | 4 | 366 | |
| Glutathione2023-11 → 2026-08 · ↑ 10% over ↓ 8% under | 528 | 99.7% | 90% | 3 | 418 | |
| ARA-2902024-07 → 2026-08 · ↑ 61% over ↓ 3% under | 274 | 99.5% | 46% | 3 | 215 | |
| LL-372023-12 → 2026-08 · ↑ 80% over ↓ 3% under | 170 | 99.8% | 23% | 3 | 124 | |
| Thymulin2024-06 → 2026-07 · ↑ 55% over ↓ 10% under | 66 | 99.8% | 39% | 2 | 51 |
Growth Hormone Secretagogues
17 compounds| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| Tesamorelin 29 zero-purity2020-01 → 2026-08 · ↑ 59% over ↓ 10% under | 2,801 | 99.6% | 43% | 11 | 1445 | |
| Ipamorelin 8 zero-purity2021-03 → 2026-08 · ↑ 43% over ↓ 17% under | 1,288 | 99.8% | 53% | 12 | 674 | |
| CJC-1295 30 zero-purity2019-11 → 2026-08 · ↑ 45% over ↓ 22% under | 791 | 99.6% | 46% | 10 | 380 | |
| Sermorelin2022-08 → 2026-08 · ↑ 69% over ↓ 6% under | 625 | 99.3% | 36% | 10 | 373 | |
| HGH 1 zero-purity2020-02 → 2026-08 · ↑ 48% over ↓ 12% under | 262 | 96.8% | 48% | 4 | 66 | |
| CJC-1295 w/ DAC2022-08 → 2026-08 · ↑ 66% over ↓ 9% under | 197 | 99.4% | 30% | 3 | 140 | |
| GHRP-62022-07 → 2026-07 · ↑ 52% over ↓ 14% under | 109 | 99.6% | 44% | 3 | 62 | |
| GHRP-22023-05 → 2026-07 · ↑ 36% over ↓ 24% under | 76 | 99.3% | 63% | 3 | 43 | |
| Somatropin2018-04 → 2026-04 · ↑ 56% over ↓ 0% under | 74 | 96.6% | 44% | 1 | 40 | |
| IGF-1 LR32021-03 → 2026-06 · ↑ 55% over ↓ 19% under | 66 | 99.2% | 34% | 2 | 38 | |
| Hexarelin2024-01 → 2026-07 · ↑ 60% over ↓ 10% under | 46 | 99.5% | 35% | 3 | 35 | |
| CJC-1295 no DAC2024-10 → 2026-07 · ↑ 65% over ↓ 10% under | 41 | 99.4% | 42% | 4 | 25 | |
| CJC-1295 (Mod GRF 1-29)2025-03 → 2026-07 · ↑ 85% over ↓ 0% under | 25 | 99.6% | 38% | 1 | 10 | |
| Human Growth Hormone2024-07 → 2026-06 · ↑ 80% over ↓ 0% under | 13 | 97.4% | 20% | 1 | 7 | |
| rhGH2025-10 → 2026-03 · ↑ 100% over ↓ 0% under | 12 | 96.8% | 0% | 1 | 2 | |
| Ibutamoren2020-07 → 2025-01 · ↑ 33% over ↓ 22% under | 11 | 97.0% | 56% | 1 | 9 | |
| IGF-12024-03 → 2026-03 · ↑ 50% over ↓ 17% under | 9 | 99.4% | 83% | 1 | 4 |
Other Peptides
113 compounds| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| MOTS-c 5 zero-purity2023-04 → 2026-08 · ↑ 56% over ↓ 6% under | 2,545 | 99.5% | 52% | 5 | 1504 | |
| BPC-157 + Ghk-cu + Kpv + TB-5002025-01 → 2026-08 · ↑ 17% over ↓ 83% under | 1,320 | 99.7% | 0% | 1 | 1024 | |
| CJC-1295 + Ipamorelin2025-01 → 2026-08 · ↑ 85% over ↓ 15% under | 1,150 | 99.8% | 5% | 2 | 826 | |
| SS-31 1 zero-purity2023-11 → 2026-08 · ↑ 49% over ↓ 12% under | 1,046 | 99.8% | 53% | 7 | 700 | |
| BPC-157 + Ghk-cu + TB-5002024-12 → 2026-08 · ↑ 33% over ↓ 56% under | 1,014 | 99.7% | 22% | 2 | 752 | |
| Semax2023-10 → 2026-08 · ↑ 75% over ↓ 5% under | 943 | 99.5% | 31% | 5 | 692 | |
| Melanotan II 4 zero-purity2022-08 → 2026-08 · ↑ 46% over ↓ 15% under | 884 | 99.8% | 51% | 9 | 564 | |
| Selank2023-04 → 2026-08 · ↑ 69% over ↓ 8% under | 855 | 99.8% | 34% | 3 | 611 | |
| Epithalon2023-04 → 2026-08 · ↑ 50% over ↓ 9% under | 819 | 99.6% | 53% | 4 | 524 | |
| Glp Sm2025-01 → 2026-08 · ↑ 79% over ↓ 4% under | 793 | 99.8% | 27% | 1 | 395 | |
| PT-141 2 zero-purity2022-11 → 2026-08 · ↑ 43% over ↓ 17% under | 777 | 99.9% | 54% | 11 | 510 | |
| DSIP2023-11 → 2026-08 · ↑ 59% over ↓ 14% under | 616 | 99.3% | 38% | 4 | 416 | |
| AOD-96042023-09 → 2026-08 · ↑ 55% over ↓ 14% under | 584 | 99.6% | 43% | 3 | 379 | |
| IGF-LR32025-01 → 2026-08 · ↑ 68% over ↓ 15% under | 391 | 99.2% | 26% | 1 | 298 | |
| Kisspeptin2023-11 → 2026-08 · ↑ 54% over ↓ 20% under | 381 | 99.6% | 41% | 3 | 291 | |
| Melanotan I2024-06 → 2026-08 · ↑ 60% over ↓ 3% under | 322 | 99.8% | 50% | 3 | 238 | |
| Ipamorelin + Tesamorelin2025-01 → 2026-08 · ↑ 67% over ↓ 33% under | 233 | 99.6% | 0% | 2 | 132 | |
| Pinealon2024-11 → 2026-08 · ↑ 49% over ↓ 16% under | 210 | 99.6% | 45% | 3 | 147 | |
| Oxytocin2024-03 → 2026-08 · ↑ 54% over ↓ 16% under | 198 | 99.2% | 45% | 2 | 137 | |
| Slu Pp 3322025-05 → 2026-08 · ↑ 40% over ↓ 23% under | 187 | 99.8% | 48% | 2 | 135 | |
| SNAP-82024-06 → 2026-08 · ↑ 82% over ↓ 1% under | 183 | 99.6% | 28% | 2 | 124 | |
| Cartalax2023-10 → 2026-08 · ↑ 44% over ↓ 12% under | 152 | 99.6% | 61% | 3 | 118 | |
| VIP2025-04 → 2026-08 · ↑ 24% over ↓ 34% under | 146 | 99.3% | 66% | 2 | 118 | |
| Fox04-dri2024-06 → 2026-08 · ↑ 48% over ↓ 13% under | 86 | 99.6% | 56% | 2 | 77 | |
| Cagrilintide/glp Rt2025-11 → 2026-07 | 84 | 99.9% | — | 1 | 48 | |
| Selank + Semax2025-01 → 2026-08 | 84 | 99.5% | — | 1 | 60 | |
| Ahk-cu2025-01 → 2026-08 · ↑ 26% over ↓ 13% under | 73 | 99.6% | 72% | 2 | 64 | |
| N-acetyl Semax Amidate2024-04 → 2026-08 · ↑ 73% over ↓ 9% under | 68 | 99.6% | 34% | 2 | 49 | |
| Carnitine2025-11 → 2026-07 · ↑ 9% over ↓ 4% under | 65 | 99.7% | 91% | 1 | 51 | |
| PE-22-282024-06 → 2026-08 · ↑ 38% over ↓ 10% under | 59 | 99.7% | 62% | 2 | 44 | |
| N-Acetyl Selank Amidate2024-04 → 2026-08 · ↑ 76% over ↓ 0% under | 57 | 99.8% | 29% | 2 | 41 | |
| hCG2023-12 → 2026-07 · ↑ 62% over ↓ 24% under | 53 | 98.2% | 16% | 2 | 19 | |
| Adamax2024-09 → 2026-08 · ↑ 96% over ↓ 0% under | 48 | 99.6% | 13% | 2 | 42 | |
| Cagrilintide/glp Sm2025-11 → 2026-07 | 48 | 99.8% | — | 1 | 40 | |
| Confirmed2026-05 → 2026-07 · ↑ 50% over ↓ 7% under | 43 | 99.8% | 61% | 1 | 21 | |
| PNC-272024-06 → 2026-07 · ↑ 41% over ↓ 12% under | 40 | 99.5% | 53% | 2 | 32 | |
| Testagen2025-04 → 2026-08 · ↑ 55% over ↓ 10% under | 38 | 99.7% | 45% | 2 | 32 | |
| Thymalin2023-11 → 2026-07 · ↑ 39% over ↓ 10% under | 36 | 99.6% | 58% | 2 | 26 | |
| Vesugen2024-11 → 2026-08 · ↑ 37% over ↓ 10% under | 35 | 99.8% | 73% | 2 | 29 | |
| Prostamax2024-06 → 2026-08 · ↑ 46% over ↓ 11% under | 34 | 99.6% | 54% | 2 | 24 | |
| Cardiogen2025-02 → 2026-08 · ↑ 40% over ↓ 12% under | 33 | 99.7% | 72% | 2 | 27 | |
| Ghk-cu + Kpv2026-01 → 2026-07 | 33 | 99.8% | — | 1 | 27 | |
| Vilon2025-05 → 2026-08 · ↑ 35% over ↓ 15% under | 33 | 99.5% | 58% | 2 | 26 | |
| N-acetyl Semax2025-06 → 2026-08 · ↑ 69% over ↓ 0% under | 32 | 99.6% | 38% | 2 | 21 | |
| Cortagen2025-02 → 2026-08 · ↑ 74% over ↓ 9% under | 31 | 99.5% | 57% | 2 | 27 | |
| Glp Rt/glp Tz2025-10 → 2026-08 | 31 | 99.9% | — | 1 | 18 | |
| Dihexa2025-06 → 2026-08 · ↑ 52% over ↓ 19% under | 30 | 99.5% | 29% | 2 | 24 | |
| Benzyl Alcohol2025-11 → 2026-08 | 28 | 99.8% | — | 1 | 22 | |
| Blend (unspecified)2025-06 → 2026-03 · ↑ 0% over ↓ 100% under | 27 | 99.2% | 0% | 1 | 18 | |
| Bronchogen2025-02 → 2026-07 · ↑ 69% over ↓ 0% under | 27 | 99.6% | 44% | 2 | 23 | |
| Ovagen2025-02 → 2026-07 · ↑ 26% over ↓ 13% under | 27 | 99.1% | 70% | 2 | 19 | |
| Cyanocobalamin (vitamin B12)2025-10 → 2026-08 · ↑ 69% over ↓ 8% under | 25 | 99.6% | 38% | 1 | 23 | |
| Livagen2025-03 → 2026-08 · ↑ 42% over ↓ 16% under | 25 | 99.7% | 42% | 2 | 22 | |
| Adamax (984DA)2026-07 → 2026-08 · ↑ 75% over ↓ 5% under | 24 | 99.8% | 30% | 1 | 24 | |
| Nad+/5-amino 1mq/mots-c2026-01 → 2026-08 · ↑ 100% over ↓ 0% under | 24 | 99.9% | 0% | 1 | 21 | |
| BPC-157 + Kpv + TB-5002025-10 → 2026-07 | 23 | 99.5% | — | 1 | 22 | |
| Chonluten2025-02 → 2026-06 · ↑ 50% over ↓ 6% under | 22 | 99.6% | 50% | 2 | 18 | |
| Cyanocobalamin (B12)2025-10 → 2026-06 · ↑ 60% over ↓ 20% under | 22 | 99.1% | 60% | 1 | 22 | |
| Eloralintide2026-01 → 2026-08 · ↑ 62% over ↓ 10% under | 22 | 99.8% | 43% | 2 | 18 | |
| Ghk-cu/ac-sdkp/bpc-1572026-04 → 2026-08 | 22 | 99.7% | — | 1 | 22 | |
| Gonadorelin2025-01 → 2026-07 · ↑ 53% over ↓ 7% under | 22 | 99.9% | 47% | 1 | 19 | |
| Frag 1762025-06 → 2026-08 · ↑ 78% over ↓ 11% under | 21 | 99.7% | 22% | 1 | 18 | |
| Ac-sdkp/bpc-1572026-04 → 2026-07 | 20 | 99.3% | — | 1 | 18 | |
| N-acetyl Selank2025-04 → 2026-08 · ↑ 60% over ↓ 0% under | 20 | 99.6% | 47% | 2 | 13 | |
| Aicar2025-09 → 2026-07 · ↑ 59% over ↓ 6% under | 19 | 99.7% | 47% | 2 | 17 | |
| Ac-sdkp2026-05 → 2026-08 · ↑ 73% over ↓ 0% under | 17 | 99.8% | 27% | 1 | 17 | |
| Adipotide2024-06 → 2026-07 · ↑ 50% over ↓ 19% under | 17 | 99.2% | 38% | 3 | 10 | |
| Methylene Blue2025-05 → 2026-08 · ↑ 42% over ↓ 8% under | 17 | 98.5% | 58% | 1 | 14 | |
| Pancragen2025-06 → 2026-07 · ↑ 50% over ↓ 0% under | 17 | 99.7% | 58% | 2 | 16 | |
| Mgf Peptide2025-07 → 2026-06 · ↑ 54% over ↓ 8% under | 16 | 99.8% | 46% | 1 | 16 | |
| Mk 6772020-06 → 2026-08 · ↑ 12% over ↓ 12% under | 16 | 99.1% | 88% | 2 | 11 | |
| ACE-0312025-09 → 2026-07 · ↑ 57% over ↓ 21% under | 15 | 99.5% | 21% | 2 | 13 | |
| Cagrilintide + Semaglutide2024-06 → 2026-03 · ↑ 0% over ↓ 100% under | 15 | 99.7% | 0% | 2 | 11 | |
| Cagrilintide/peptide C2026-04 → 2026-07 | 15 | 99.8% | — | 1 | 4 | |
| Humanin2023-10 → 2026-05 · ↑ 15% over ↓ 38% under | 15 | 96.6% | 54% | 2 | 13 | |
| Thymogen2025-09 → 2026-07 · ↑ 82% over ↓ 9% under | 15 | 98.4% | 18% | 2 | 13 | |
| Tirzepatide/glycine2025-09 → 2025-10 · ↑ 55% over ↓ 0% under | 15 | 99.6% | 64% | 1 | 10 | |
| Crystagen2025-04 → 2026-06 · ↑ 31% over ↓ 0% under | 14 | 99.7% | 77% | 2 | 7 | |
| CJC-1295 + Ipamorelin + Tesamorelin2026-01 → 2026-08 | 13 | 99.5% | — | 1 | 12 | |
| Enclomiphene2022-07 → 2026-08 · ↑ 0% over ↓ 40% under | 13 | 99.8% | 100% | 2 | 11 | |
| Ghk-cu/kpv + Ac-sdkp/bpc-1572026-05 → 2026-07 | 13 | 99.9% | — | 1 | 13 | |
| L-carnitine2025-02 → 2026-01 · ↑ 0% over ↓ 50% under | 13 | 99.2% | 50% | 1 | 13 | |
| Mgf2025-03 → 2026-04 · ↑ 30% over ↓ 20% under | 13 | 99.6% | 50% | 3 | 8 | |
| Dermorphin2025-04 → 2026-07 · ↑ 64% over ↓ 27% under | 12 | 99.7% | 36% | 2 | 9 | |
| Rta2026-06 → 2026-07 · ↑ 42% over ↓ 0% under | 12 | 99.9% | 83% | 1 | 1 | |
| AOD 2 zero-purity2025-01 → 2026-05 · ↑ 25% over ↓ 12% under | 11 | 99.3% | 62% | 3 | 6 | |
| BPC-157 + Ghk-cu + Kpv2026-01 → 2026-08 | 11 | 99.8% | — | 1 | 10 | |
| Cagrilintide + Retatrutide2025-06 → 2025-10 | 11 | 99.9% | — | 1 | 5 | |
| Gonadotropin2024-06 → 2026-01 · ↑ 64% over ↓ 9% under | 11 | — | 55% | 1 | 6 | |
| N-acetyl Epitalon Amidate2026-03 → 2026-08 · ↑ 20% over ↓ 20% under | 11 | 99.7% | 70% | 1 | 9 | |
| Orforglipron2025-09 → 2026-07 · ↑ 12% over ↓ 12% under | 11 | 99.6% | 88% | 2 | 10 | |
| Adamax (low Mw)2026-05 → 2026-06 · ↑ 100% over ↓ 0% under | 10 | 99.9% | 0% | 1 | 10 | |
| Bac Water2026-05 → 2026-07 · ↑ 100% over ↓ 0% under | 10 | 99.7% | 0% | 1 | 7 | |
| Peg Mgf2025-07 → 2026-02 · ↑ 43% over ↓ 14% under | 10 | 99.1% | 43% | 2 | 7 | |
| BAM-152025-05 → 2026-07 · ↑ 0% over ↓ 33% under | 9 | 99.8% | 83% | 2 | 7 | |
| FOX042025-07 → 2025-11 · ↑ 14% over ↓ 29% under | 9 | 99.7% | 86% | 2 | 9 | |
| FOXO42025-03 → 2026-01 · ↑ 33% over ↓ 0% under | 9 | 99.4% | 67% | 1 | 6 | |
| GLP-32025-10 → 2026-07 · ↑ 78% over ↓ 0% under | 9 | 99.9% | 22% | 1 | 7 | |
| Ipamorelin + Sermorelin2025-08 → 2026-08 · ↑ 100% over ↓ 0% under | 9 | 99.6% | 0% | 1 | 5 | |
| L-glutathione2024-12 → 2026-04 · ↑ 29% over ↓ 0% under | 9 | 99.9% | 100% | 3 | 5 | |
| Methylcobalamin (B12)2026-04 → 2026-07 · ↑ 100% over ↓ 0% under | 9 | 99.6% | 0% | 1 | 8 | |
| Noopept2023-09 → 2026-08 · ↑ 0% over ↓ 0% under | 9 | 99.4% | 100% | 2 | 5 | |
| P-212024-08 → 2026-05 · ↑ 75% over ↓ 12% under | 9 | 99.2% | 12% | 2 | 4 | |
| Retatrutide/glycine2025-09 → 2025-10 · ↑ 62% over ↓ 0% under | 9 | 100.0% | 38% | 1 | 8 | |
| TB-500 (TB4)2024-11 → 2026-05 · ↑ 20% over ↓ 20% under | 9 | 99.4% | 80% | 2 | 6 | |
| Vesilute2025-12 → 2026-07 · ↑ 12% over ↓ 0% under | 9 | 99.6% | 88% | 1 | 9 | |
| Acadesine (aicar)2026-06 → 2026-08 · ↑ 62% over ↓ 0% under | 8 | 99.8% | 50% | 1 | 8 | |
| BPC-157 + Ghk-cu2025-05 → 2026-07 | 8 | 99.6% | — | 1 | 8 | |
| BPC/TB4 102026-05 → 2026-05 | 8 | 99.4% | — | 1 | 1 | |
| PE22-282025-09 → 2026-08 · ↑ 0% over ↓ 67% under | 8 | 99.5% | 33% | 1 | 8 | |
| Peptide C2026-02 → 2026-06 · ↑ 60% over ↓ 0% under | 8 | 99.7% | 60% | 1 | 4 | |
| S-232020-06 → 2026-06 · ↑ 20% over ↓ 0% under | 8 | 98.0% | 80% | 2 | 5 | |
| Vardenafil2020-07 → 2026-07 · ↑ 25% over ↓ 25% under | 8 | 99.9% | 50% | 2 | 6 |
SARMs
4 compounds| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| RAD-1402020-03 → 2026-07 · ↑ 8% over ↓ 0% under | 18 | 97.0% | 92% | 2 | 7 | |
| Cardarine (GW-501516)2021-05 → 2026-06 · ↑ 20% over ↓ 20% under | 13 | 98.0% | 80% | 2 | 10 | |
| Ostarine2021-05 → 2025-03 · ↑ 12% over ↓ 0% under | 10 | 98.0% | 100% | 1 | 6 | |
| YK-112020-06 → 2026-07 · ↑ 38% over ↓ 12% under | 10 | 98.7% | 75% | 2 | 5 |
Oral Steroids / AAS
20 compounds| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| Oxandrolone2020-01 → 2026-07 · ↑ 38% over ↓ 9% under | 160 | 98.0% | 63% | 1 | 51 | |
| Stanozolol2019-03 → 2026-07 · ↑ 29% over ↓ 15% under | 94 | 96.0% | 69% | 1 | 38 | |
| Methandienone2019-08 → 2026-07 · ↑ 35% over ↓ 7% under | 82 | 98.0% | 72% | 1 | 34 | |
| Oxymetholone2018-12 → 2026-04 · ↑ 12% over ↓ 26% under | 62 | 95.9% | 74% | 1 | 27 | |
| Turinabol2020-05 → 2026-07 · ↑ 36% over ↓ 5% under | 44 | 98.0% | 72% | 1 | 17 | |
| Methenolone Enanthate2019-11 → 2026-07 · ↑ 50% over ↓ 0% under | 42 | 97.0% | 50% | 1 | 19 | |
| Mesterolone2019-10 → 2026-07 · ↑ 19% over ↓ 19% under | 41 | 98.0% | 73% | 1 | 18 | |
| Trenbolone Acetate2019-03 → 2026-07 · ↑ 0% over ↓ 0% under | 41 | 98.0% | 100% | 1 | 22 | |
| Testosterone Propionate2021-07 → 2026-02 · ↑ 0% over ↓ 0% under | 27 | 98.0% | 100% | 1 | 13 | |
| Drostanolone Propionate2019-11 → 2025-10 · ↑ 0% over ↓ 0% under | 22 | 98.2% | 100% | 1 | 15 | |
| Fluoxymesterone2020-05 → 2025-12 · ↑ 25% over ↓ 19% under | 20 | 95.4% | 75% | 1 | 8 | |
| Testosterone Cypionate2021-08 → 2026-07 | 20 | 96.0% | — | 1 | 8 | |
| Nandrolone Phenylpropionate2020-11 → 2026-05 | 18 | 97.0% | — | 1 | 12 | |
| Testosterone Enanthate2020-01 → 2026-04 · ↑ 0% over ↓ 0% under | 16 | 98.0% | 100% | 1 | 4 | |
| Methasterone2021-05 → 2026-02 · ↑ 25% over ↓ 8% under | 13 | 92.1% | 75% | 1 | 3 | |
| Trenbolone Enanthate2021-01 → 2026-02 | 10 | 97.0% | — | 1 | 2 | |
| Nandrolone Decanoate2020-01 → 2026-05 | 9 | 95.5% | — | 1 | 3 | |
| Trenbolone Hexahydrobenzylcarbonate2022-04 → 2026-07 | 9 | 98.0% | — | 1 | 4 | |
| Boldenone Undecylenate2020-11 → 2025-12 | 8 | 97.0% | — | 1 | 5 | |
| Drostanolone Enanthate2020-09 → 2025-04 | 8 | 96.1% | — | 1 | 2 |
Small Molecules
17 compounds| Compound | Certs | Median purity | Dose ±10% | Labs | Vendors | Open compound |
|---|---|---|---|---|---|---|
| NAD+ 5 zero-purity2024-02 → 2026-08 · ↑ 38% over ↓ 10% under | 1,957 | 99.9% | 66% | 5 | 1210 | |
| 5-Amino-1MQ2025-01 → 2026-08 · ↑ 56% over ↓ 14% under | 653 | 99.7% | 43% | 3 | 466 | |
| Tadalafil2017-11 → 2026-06 · ↑ 36% over ↓ 7% under | 51 | 98.0% | 67% | 2 | 19 | |
| Tesofensine2023-01 → 2026-07 · ↑ 42% over ↓ 17% under | 46 | 99.4% | 44% | 2 | 37 | |
| Anastrozole2019-09 → 2026-02 · ↑ 42% over ↓ 19% under | 33 | 89.3% | 58% | 1 | 16 | |
| Exemestane2018-12 → 2026-06 · ↑ 10% over ↓ 14% under | 32 | 96.0% | 76% | 1 | 13 | |
| Clomiphene Citrate2020-02 → 2025-11 · ↑ 9% over ↓ 4% under | 27 | 98.0% | 100% | 1 | 11 | |
| Clenbuterol2020-11 → 2026-02 · ↑ 41% over ↓ 27% under | 23 | 92.3% | 41% | 1 | 12 | |
| Letrozole2019-08 → 2026-06 · ↑ 35% over ↓ 10% under | 22 | 98.0% | 80% | 2 | 10 | |
| Tamoxifen Citrate2020-01 → 2024-10 · ↑ 38% over ↓ 10% under | 21 | — | 52% | 1 | 6 | |
| Tamoxifen2019-08 → 2025-10 · ↑ 25% over ↓ 12% under | 18 | 96.7% | 75% | 1 | 11 | |
| Cabergoline2021-02 → 2025-11 · ↑ 38% over ↓ 31% under | 13 | — | 54% | 1 | 8 | |
| Sildenafil2017-11 → 2026-05 · ↑ 36% over ↓ 18% under | 13 | 96.0% | 64% | 2 | 8 | |
| 5-Amino-1-Methylquinolinium2025-04 → 2026-05 · ↑ 58% over ↓ 8% under | 12 | — | 33% | 1 | 8 | |
| Clomiphene2023-03 → 2025-06 · ↑ 38% over ↓ 38% under | 8 | — | 75% | 1 | 7 | |
| Isotretinoin2021-05 → 2026-06 · ↑ 0% over ↓ 75% under | 8 | — | 38% | 1 | 2 | |
| Raloxifene2017-11 → 2024-02 · ↑ 17% over ↓ 17% under | 8 | 96.3% | 83% | 1 | 1 |
No compounds match .
Try a shorter term, a short code (e.g. BPC), or clear the box to see all 187.
How to read these figures
Median purityMedian reported %purity across this compound's published certificates. ≥99 reads green, under 90 red; everything between stays neutral.
Dose passShare of certs whose tested quantity lands within ±10% of the labeled dose. ≥90 50–89 <50.
Dose splitUnder each compound: of the certs carrying a tested-vs-label dose, the share overdosed (≥ +7% over the labeled dose) and underdosed (≤ −7% under). The remainder land close to label.
Labs / VendorsDistinct independent labs, and distinct vendors, represented in the corpus for that compound.
Zero-purityCertificates where the lab found 0% of the labeled compound, a direct mislabel or fraud signal. Always open the individual cert.